Efficacy of topical sensitizers in the treatment of alopecia areata

      Abstract

      It has been more than 2 decades since the first report of the use of dinitrochlorobenzene to induce hair growth in 2 patients with alopecia areata. Other topical sensitizers, namely squaric acid dibutylester and diphenylcyclopropenone, have been used with variable success. This article reviews the efficacy and safety of the use of topical sensitizers in the treatment of alopecia areata. (J Am Acad Dermatol 1998;39:751-61.)
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rosenberg E
        • Drake L.
        Alopecia areata.
        Arch Dermatol. 1976; 112 ([letter]): 256
        • Summer K
        • Goggelmann W.
        1-Chloro-2,4-dinitrochlorobenzene depletes glutathione in rat skin and is mutagenic.
        Mutat Res. 1980; 77: 91-93
        • Wilkerson MG
        • Wilkin JK
        • Smith RG.
        Contaminants of dinitrochlorobenzene.
        J Am Acad Dermatol. 1983; 9: 554-557
        • Feldman RJ
        • Maibach HI.
        Absorption of some organic compounds through the skin in man.
        J Invest Dermatol. 1970; 54: 399-404
        • Noster U
        • Hausen B
        • Krische B
        • Schulz K.
        Squaric-acid-diethylester: a strong sensitizer.
        Contact Dermatitis. 1976; 2: 99-104
        • Claudy AL
        • Roche H.
        Traitement des verrues multiples et recidivantes par induction d’une hypersensibilte retarde.
        Ann Dermatol Venereol. 1981; 108: 765-767
        • Shapiro J.
        Alopecia areata: update on therapy.
        Dermatol Clin. 1993; 11: 35-46
        • Wilkerson MG
        • Henkin J
        • Wilkin JK.
        Diphenylcyclo-propenone: examination for potential contaminants, mechanisms of sensitization, and photochemical stability.
        J Am Acad Dermatol. 1984; 11: 802-807
        • Wilkerson M
        • Henkin J
        • Wilkin JK
        • Smith RG.
        Squaric acid and esters: analysis for contaminants and stability in solvents.
        J Am Acad Dermatol. 1985; 13: 229-234
        • Strobel R
        • Rohrborn G.
        Mutagenic and cell transformation activities of 1-chlor-2,4-dinitrobenzene and squaric acid dibutylester.
        Arch Toxicol. 1980; 435: 307-314
        • van Duuren B
        • Melchionne S
        • Blair R
        • et al.
        Carcinogenicity of isosters of epoxides and lactones: azirdine ethanol, propane sulfone, and related compounds.
        J Natl Cancer Inst. 1971; 46: 143-149
        • Lane PR
        • Hogan DJ.
        Diphencyprone.
        J Am Acad Dermatol. 1988; 19 ([letter]): 364-365
        • Hartland C
        • Saihan E.
        Regression of cutaneous metastatic melanoma with topical diphencyprone and oral cimet-idine.
        Lancet. 1989; 2: 455
        • Perret C
        • Steiljen P
        • Happle R.
        Alopecia areata: pathogenesis and topical immunotherapy.
        Int J Dermatol. 1990; 29: 83-88
        • Wilkerson M
        • Connor TH
        • Henkin J
        • Wilkin JK
        • Matney TS.
        Assessment of diphenylcyclopropenone for photochemically induced mutagenicity in the Ames assay.
        J Am Acad Dermatol. 1987; 17: 606-611
        • Stute J
        • Hausen BM
        • Schulz KH.
        Diphenylcyclo-propenone: a new strong contact sensitizer.
        Dermatol Beruf Umwelt. 1981; 29 (Author’s translation): 12-14
        • van der Steen PHM
        • van Baar HMJ
        • Perret CM
        • Happle R.
        Treatment of alopecia areata with diphenylcyclopropenone.
        J Am Acad Dermatol. 1991; 24: 253-257
        • Shapiro J.
        Topical immunotherapy in the treatment of chronic severe alopecia areata.
        Dermatol Clin. 1993; 11: 611
        • Berth-Jones J
        • McBurney A
        • Hutchinson P.
        Diphen-cyprone is not detectable in serum or urine following topical application.
        Acta Derm Venereol (Stockh). 1994; 74: 312-313
        • Happle R.
        Topical immunotherapy in alopecia areata.
        J Invest Dermatol. 1991; 96: 71S
        • Happle R
        • Klein H
        • Macher E.
        Topical immunotherapy changes in the composition of the peribulbar infiltrate in alopecia areata.
        Arch Dermatol Res. 1986; 278: 214-218
        • Bröcker EB
        • Echternacht-Happle K
        • Hamm H
        • Happle R.
        Abnormal expression of class I and class II major histocompatibility antigens in alopecia areata modulation by topical immunotherapy.
        J Invest Dermatol. 1987; 88: 564-568
        • Johansson E
        • Rank A
        • et al.
        Immunohistological evaluation of alopecia areata treated with squaric acid dibutylester.
        Acta Derm Venereol (Stockh). 1987; 66: 485-490
        • Bröcker EB
        • John S
        • Steinhausen D
        • Hamm H.
        Topical immunotherapy with contact allergens in alopecia areata: evidence for non-specific systemic suppression of cellular immune reactions.
        Arch Dermatol Res. 1991; 283: 133-134
        • Happle R
        • Kalveran K
        • Buchner U
        • Echternacht-Happle K
        • Goggelman W
        • Summer KH.
        Contact allergy as a therapeutic tool for alopecia areata: application of squaric acid dibutylester.
        Dermatologica. 1980; 161: 289-297
        • Micali G
        • Licastro-Cicero R
        • Nasca MR
        • et al.
        Treatment of alopecia areata with squaric acid dibutylester.
        Int J Dermatol. 1996; 35: 52-56
        • Valsecchi R
        • Cainelli T
        • Foiadelli L
        • Rossi A.
        Topical immunotherapy of alopecia areata: a follow-up study.
        Acta Derm Venereol (Stockh). 1986; 66: 269-272
        • van der Steen P
        • Happle R.
        Castling phenomenon.
        Eur J Dermatol. 1992; 2: 151-153
        • Orecchia G.
        The “castling” phenomenon: a possible explanation.
        Eur J Dermatol. 1994; 4 ([letter]): 161
        • van der Steen P
        • Happle R.
        Topical immunotherapy of alopecia areata.
        Dermatol Clin. 1993; 11: 619-622
        • Case PC
        • Mitchell AJ
        • Swanson NA
        • Vanderveen EE
        • Ellis CN
        • Headington J.
        Topical therapy of alopecia areata with squaric acid dibutylester.
        J Am Acad Dermatol. 1984; 10: 447-451
        • Fanti P
        • Tosti A
        • Bardazzi F
        • Guerra L.
        Alopecia areata: a pathological study of nonresponder patients.
        Am J Dermatopathol. 1994; 16: 167-170
        • Happle R
        • Cebulla K
        • Echternacht-Happle K.
        Dinitrochlorobenzene therapy for alopecia areata.
        Arch Dermatol. 1978; 114: 1629-1631
        • Orecchia G
        • Rabbiosi G.
        Treatment of alopecia areata with diphencyprone.
        Dermatologica. 1985; 171: 193-196
        • Breuillard F
        • Szapiro E.
        Cimetidine in acquired tolerance to dinitrochlorobenzene.
        Lancet. 1978; 1: 726
        • Daman L
        • Rosenberg E.
        Acquired tolerance to dinitrochlorobenzene reversed by cimetidine.
        Lancet. 1977; 2 ([letter]): 1087
        • Avella J
        • Binder H
        • Madsen JE
        • Binder HJ
        • Askenase PW.
        Effect of histamine H2-receptor antagonists on delayed hypersensitivity.
        Lancet. 1978; 1: 624-626
        • Rocklin R.
        Modulation of cellular immune responses in-vivo and in-vitro by histamine receptor-bearing lymphocytes.
        J Clin Invest. 1976; 57: 1051-1058
        • Gordon P
        • Aldridge G
        • McVittie E
        • Hunter J.
        Topical diphencyprone for alopecia areata: evaluation of 48 cases after 30 months’ follow-up.
        Br J Dermatol. 1996; 134: 869-871
        • Friedmann PS.
        Response of alopecia areata to dinitrochlorobenzene: influence of auto-antibodies and route of sensitization.
        Br J Dermatol. 1981; 105: 285-289
        • Tosti A
        • Guidetti MS
        • Bardazzi F
        • Misciali C.
        Long-term results of topical immunotherapy in children with alopecia totalis or alopecia universalis.
        J Am Acad Dermatol. 1996; 35: 199-201
        • Orecchia G
        • Malagoli P
        • Santagostino L.
        Treatment of severe alopecia areata with squaric acid dibutylester in pediatric patients.
        Pediatr Dermatol. 1994; 11: 65-68
        • Caserio R.
        Treatment of alopecia areata with squaric acid dibutylester.
        Arch Dermatol. 1987; 123: 1036-1041
        • Tosti A
        • De Padova MP
        • Minghetti G
        • Veronesi S.
        Therapies versus placebo in the treatment of patchy alopecia areata.
        J Am Acad Dermatol. 1986; 15: 209-210
        • Valsecchi R
        • Cainelli T
        • Tornahi A
        • et al.
        Squaric acid dibutylester treatment of alopecia areata.
        Clin Exp Dermatol. 1985; 10: 233-238
        • Barth J
        • Darley C
        • Gibson J.
        Squaric acid dibutylester in the treatment of alopecia areata.
        Dermatologica. 1985; 170: 40-42
        • Giannetti A
        • Orecchia G.
        Clinical experience on the treatment of alopecia areata with squaric acid dibutylester.
        Dermatologica. 1983; 167: 280-282
        • Flowers F
        • Slazinski L
        • Fenske N
        • Pullano TJ.
        Topical squaric acid dibutylester therapy for alopecia areata.
        Cutis. 1982; 30: 733-736
        • Schuttelaar M
        • Hamstra J
        • Plinck E
        • et al.
        Alopecia areata in children: treatment with diphencyprone.
        Br J Dermatol. 1996; 135: 581-585
        • Shapiro J
        • Tan J
        • Tron V.
        Diphencyprone and minoxidil in alopecia areata: a clinical and immonopathological evaluation.
        J Invest Dermatol. 1995; 104: 36S
        • Hoting E
        • Boehm A.
        Therapy of alopecia areata with diphencyprone.
        Br J Dermatol. 1992; 127: 625-629
        • van der Steen P
        • Boezeman J
        • Happle R.
        Topical immunotherapy for alopecia areata: re-evaluation of 139 cases after additional follow-up period of 19 months.
        Dermatology. 1992; 184: 198-201
        • van der Steen PHM
        • van Baar HMJ
        • Happle R
        • Boezeman JBM
        • Perret CM.
        Prognostic factors in the treatment of alopcia areata with diphenylcyclopropenone.
        J Am Acad Dermatol. 1991; 24: 227-230
        • MacDonald-Hull S
        • Pepall L
        • Cunliffe W.
        Alopecia areata in children: response to treatment with diphencyprone.
        Br J Dermatol. 1991; 125: 164-168
        • MacDonald-Hull S
        • Cunliffe W.
        Successful treatment of alopecia areata using the contact allergen diphencyprone.
        Br J Dermatol. 1991; 123 ([letter]): 212
        • Ashworth J
        • Tuyp E
        • MacKie R.
        Allergic and irritant contact dermatitis in the treatment of alopecia totalis and universalis: a comparison of the value of topical diphencyprone and tretinoin gel.
        Br J Dermatol. 1989; 120: 397-401
        • Monk B.
        Induction of hair growth in alopecia totalis with diphencyprone sensitization.
        Clin Exp Dermatol. 1989; 14: 154-157
        • MacDonald-Hull S
        • Norris J.
        Diphencyprone in the treatment of long-standing alopecia areata.
        Br J Dermatol. 1988; 119: 367-374
        • Hatzis J
        • Georgiotouo K
        • Kostakis P.
        Treatment of alopecia areata with diphencyprone.
        Australas J Dermatol. 1988; 29: 33-36
        • Happle R
        • Hausen B
        • Wiesner-Menzel L.
        Diphencyprone in the treatment of alopecia areata.
        Acta Derm Venereol (Stockh). 1983; 63: 49-52
        • MacDonald-Hull S
        • Cunliffe W
        • Norris J.
        Alopecia areata treated with diphencyprone: Is an allergic response necessary?.
        Br J Dermatol. 1990; 122 ([letter]): 716-717
        • Naldi L
        • Parazzini F
        • Cainelli T
        • Reading Group
        Role of topical immunotherapy in the treatment of alopecia areata.
        J Am Acad Dermatol. 1990; 22: 654-656
        • MacDonald-Hull S
        • Cunliffe W.
        Post therapy relapse rate in alopecia areata after successful treatment with diphencyprone.
        J Dermatol Treat. 1989; 1: 71-74
        • Ro B.
        Alopecia areata in Korea.
        J Dermatol. 1995; 22: 858-864
        • Orecchia G
        • Perfetti L
        • et al.
        Photochemotherapy plus squaric acid dibutylester in alopecia areata treatment.
        Dermatologica. 1990; 181 ([letter]): 167
        • Berth-Jones J
        • Hutchinson P.
        Treatment of alopecia totalis with a combination of inosine pranobex and diphencyprone compared to each treatment alone.
        Clin Exp Dermatol. 1991; 16: 172
        • Happle R
        • Echternacht K.
        Induction of hair growth in alopecia areata with dinitrochlorobenzene.
        Lancet. 1977; 2: 1002-1003
        • DeProst Y
        • Paquez F
        • Touraine R.
        Dinitrochlorobenzene treatment of alopecia areata.
        Arch Dermatol. 1982; 118: 542
        • Temmerman L
        • de Weert J
        • deKeyser L
        • Kint A
        Treatment of alopecia areata with dinitrochlorobenzene.
        Acta Derm Venereol (Stockh). 1984; 64: 441-443
        • Orecchia G
        • Malagoli P.
        Topical immunotherapy in children with alopecia areata.
        J Invest Dermatol. 1995; 104: 35S
        • Monk B
        • Williams H.
        Topical diphencyprone therapy in alopecia totalis.
        Br J Dermatol. 1988; 119: 16-17
        • van der Steen P
        • Happle R.
        Dyschromia in confetti as a side effect of topical immunotherapy with diphenylcyclopropenone.
        Arch Dermatol. 1992; 128: 518-520
        • Nasca M
        • Cicero RL
        • Innocenzi D
        • Micali G.
        Persistent allergic contact dermatitis at the site of primary sensitization with squaric acid dibutylester.
        Contact Dermatitis. 1995; 33: 438
        • Valsecchi R
        • Cainelli T.
        Depigmentation from squaric acid dibutylester.
        Contact Dermatitis. 1984; 10: 109
        • Tosti A
        • Guerra L
        • Bardazzi F.
        Contact urticaria during topical immunotherapy.
        Contact Dermatitis. 1989; 21: 196
        • Hatzis J
        • Georgiotouo K
        • Tosca A.
        Vitiligo as a reaction to topical treatment with diphencyprone.
        Dermatologica. 1988; 177: 146